Write in the New England Journal of Medicine (identification and removal of roadblocks to the comparative effectiveness research) share three authors, their experience in running a head-to-head study of AVASTIN (bevacizumab) versus Lucentis (ranibizumab), for wet age-related macular degeneration (AMD). Describe the barriers facing you and suggest that you need for comparative effectiveness research be removed
View the Original article
No comments:
Post a Comment